Arrowhead Pharmaceuticals Inc
ARWR
Company Profile
Business description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Contact
177 E Colorado Boulevard
Suite 700
PasadenaCA91105
USAT: +1 626 304-3400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
711
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,096.20 | 77.60 | 0.86% |
| CAC 40 | 8,103.85 | 17.22 | -0.21% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,442.41 | 79.73 | 0.16% |
| FTSE 100 | 9,889.22 | 23.25 | 0.24% |
| HKSE | 25,774.14 | 27.63 | -0.11% |
| NASDAQ | 23,561.84 | 133.02 | 0.57% |
| Nikkei 225 | 50,412.87 | 10.48 | 0.02% |
| NZX 50 Index | 13,512.34 | 5.39 | -0.04% |
| S&P 500 | 6,909.79 | 31.30 | 0.46% |
| S&P/ASX 200 | 8,795.70 | 78.80 | 0.90% |
| SSE Composite Index | 3,919.98 | 2.61 | 0.07% |